Overactive NF‑κB signaling in myeloproliferative neoplasms
Dysregulated NFkB Pathway Signaling In Myeloproliferative Neoplasms
This project looks at whether blocking an overactive cell-signaling pathway called NF‑κB can slow or stop disease progression in people with myeloproliferative neoplasms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11238087 on NIH RePORTER |
What this research studies
Researchers will study blood and bone marrow samples from people with MPNs and run complementary experiments in mouse models to understand how NF‑κB signaling drives disease. The team will measure NF‑κB activity in patient cells and compare those findings to what they see in mice. They will test drugs or genetic approaches that reduce NF‑κB activity in models to see if disease features, like bone marrow fibrosis and abnormal blood counts, improve. Results could point to new treatment strategies or support future clinical trials for people with MPNs.
Who could benefit from this research
Good fit: Adults diagnosed with a myeloproliferative neoplasm (for example, polycythemia vera, essential thrombocythemia, or myelofibrosis) who can provide samples or participate at a study site.
Not a fit: People without MPNs or those seeking immediate changes to their personal medical treatment are unlikely to benefit directly from this research at this time.
Why it matters
Potential benefit: If successful, this work could lead to therapies that slow or stop disease progression and reduce symptoms for people with MPNs.
How similar studies have performed: Prior lab and animal studies suggest that blocking NF‑κB can reduce disease features, but proven benefit in human MPN patients is still limited.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Oh, Stephen — Washington University
- Study coordinator: Oh, Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.